AR042733A1 - Derivados de piridinas utilizados como inhibidores del mecanismo de intercambio na+/ca2+ - Google Patents
Derivados de piridinas utilizados como inhibidores del mecanismo de intercambio na+/ca2+Info
- Publication number
- AR042733A1 AR042733A1 ARP040100052A ARP040100052A AR042733A1 AR 042733 A1 AR042733 A1 AR 042733A1 AR P040100052 A ARP040100052 A AR P040100052A AR P040100052 A ARP040100052 A AR P040100052A AR 042733 A1 AR042733 A1 AR 042733A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- formula
- group
- nhc
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos con actividad terapéutica de fórmula (1) o (2), donde X es -O-, -CH2- o -C(O)-; Z es -CHR12- o un enlace de valencia; Y es -CH2-, -C(O)-, CH(OR13)-, -O-, S-; con la condición de que cuando Z es una enlace de valencia, Y no es C(O); la línea punteada representa un doble enlace optativo, en cuyo caso Z es -CR12- e Y es -CH2-, -C(O)- o -CH(OR10)- (en la fórmula 2) o -CH- (en la fórmula 1); R2 y R3 son independientemente H, alquilo inferior, alcoxi inferior, -NO2, halógeno, -CF3, -OH, benciloxi o un grupo de fórmula (3); R1 es H, CN, halógeno, -CONH2, -COOR15, -CH2NR15R18, NHC(O)R5, NHCH2R5, NHR20, NR21R22, NHC(NH)NHCH3 o, cuando el compuesto es de fórmula (2) donde existe el doble enlace optativo o cuando R2 o R3 es benciloxi o un grupo de fórmula (3), R1 también puede ser -NO2 o NR16R17; R4 es H, NO2, CN, halógeno, -CONH2, -COOH, -CH2NH2, -NR16R17, -NHC(O)R5 o -NHC(NH)NHCH3; R5 es alquilo o carboxialquilo optativamente sustituido con 1-3 sustituyentes seleccionados del grupo compuesto por halógeno, amino e hidroxi, -CHR6NR7R8 o uno de resto de grupo de fórmula (4), W es N o CH; Q es CHR14, NR9, S u O; R6 es H o alquilo inferior; R7 y R8 son independientemente H, acilo, alquilo inferior o hidroxialquilo inferior; R9 es H, alquilo inferior o fenilo; R10 y R11 son independientemente H o alquilo inferior; R12 es H o alquilo inferior; R13 es H, alquilsulfonilo o acilo; R14 es H, -OH, -COOR15; R15 es H o alquilo inferior; R16 y R17 son independientemente H, acilo, alquilsulfonilo, -C(S)NHR18 o -C(O)NHR18; R18 es H o alquilo inferior R19 es H u -OH; R20 es un grupo piridinilo optativamente sustituido con un grupo -NO2; R21 y R22 son alquilo inferior; y sales aceptables para uso farmacéutico y ésteres de los mismos. Los compuestos son potentes inhibidores del mecanismo de intercambio Na+/Ca2+.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20030030A FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Uusia yhdisteitä |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042733A1 true AR042733A1 (es) | 2005-06-29 |
Family
ID=8565286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100052A AR042733A1 (es) | 2003-01-09 | 2004-01-08 | Derivados de piridinas utilizados como inhibidores del mecanismo de intercambio na+/ca2+ |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7482340B2 (es) |
| EP (1) | EP1583759A1 (es) |
| JP (1) | JP2006516271A (es) |
| KR (1) | KR20050095601A (es) |
| CN (1) | CN100457752C (es) |
| AR (1) | AR042733A1 (es) |
| AU (1) | AU2004203943B2 (es) |
| BR (1) | BRPI0406669A (es) |
| CA (1) | CA2512184A1 (es) |
| EA (1) | EA008539B1 (es) |
| FI (1) | FI20030030A0 (es) |
| HR (1) | HRP20050703A2 (es) |
| IL (1) | IL169435A0 (es) |
| IS (1) | IS7969A (es) |
| MX (1) | MXPA05007435A (es) |
| NO (1) | NO20053730L (es) |
| NZ (1) | NZ541087A (es) |
| PL (1) | PL378326A1 (es) |
| RS (1) | RS20050528A (es) |
| UA (1) | UA81941C2 (es) |
| WO (1) | WO2004063191A1 (es) |
| ZA (1) | ZA200505461B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20011507A0 (fi) * | 2001-07-10 | 2001-07-10 | Orion Corp | Uusia yhdisteitä |
| KR101233223B1 (ko) * | 2004-12-21 | 2013-02-14 | 제이엔씨 석유 화학 주식회사 | 크로만환을 가지는 액정 화합물, 액정 조성물 및 이 액정조성물을 함유하는 액정 표시소자 |
| JP2010519267A (ja) * | 2007-02-22 | 2010-06-03 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | 新規殺微生物剤 |
| US9346790B2 (en) * | 2010-12-06 | 2016-05-24 | Autifony Therapeutics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
| EP2524908A1 (en) | 2011-05-20 | 2012-11-21 | LEK Pharmaceuticals d.d. | Process for the preparation of alfa-substituted ketones and their application in synthesis of pharmaceutically active compounds |
| PL2567958T3 (pl) | 2011-09-12 | 2015-04-30 | Sanofi Sa | Podstawione 2-(chroman-6-yloksy)-tiazole i ich zastosowanie jako środków leczniczych |
| US8912224B2 (en) | 2011-09-12 | 2014-12-16 | Sanofi | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals |
| AU2011376746B2 (en) | 2011-09-12 | 2017-06-15 | Sanofi | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals |
| JP5941637B2 (ja) * | 2011-09-12 | 2016-06-29 | サノフイ | 置換２−（クロマン−６−イルオキシ）−チアゾール及び医薬としてのその使用 |
| WO2013144191A1 (de) * | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen |
| TWI633095B (zh) * | 2013-03-08 | 2018-08-21 | 賽諾菲公司 | 經取代－６－基氧基－環烷類及其作為醫藥品之用途 |
| GB201416186D0 (en) | 2014-09-12 | 2014-10-29 | Redx Pharma Ltd | Compounds |
| US10766860B2 (en) | 2015-03-06 | 2020-09-08 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| EP3795568A1 (en) | 2015-03-06 | 2021-03-24 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| KR102573450B1 (ko) * | 2015-08-19 | 2023-08-31 | 닛산 가가쿠 가부시키가이샤 | 액정 배향제 등에 사용되는 신규의 이미드계 중합체 |
| WO2018048943A1 (en) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
| KR102615565B1 (ko) | 2016-09-07 | 2023-12-18 | 파마케아, 인크. | 리실 옥시다제 유사 2 억제제의 용도 |
| WO2019175464A1 (en) | 2018-03-14 | 2019-09-19 | Orion Corporation | Compounds useful as inhibitors of sodium-calcium exchanger (ncx) |
| JP2023535790A (ja) | 2020-07-28 | 2023-08-21 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 縮合二環式ｒａｆ阻害薬及びその使用方法 |
| CN115850258A (zh) * | 2022-12-27 | 2023-03-28 | 东北林业大学 | 一种马赛替尼的合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2820817A (en) | 1954-02-04 | 1958-01-21 | Mcneilab Inc | Oxygenated indan compounds and method of making the same |
| BE650081A (es) | 1963-07-03 | |||
| US3862232A (en) | 1963-07-03 | 1975-01-21 | Upjohn Co | 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof |
| GB1154119A (en) | 1968-05-20 | 1969-06-04 | Merck Ag E | 3-Alkyl-Flavanones |
| JPH04113839A (ja) * | 1990-09-05 | 1992-04-15 | Mitsubishi Petrochem Co Ltd | ポリカーボネート樹脂積層物 |
| FR2733685B1 (fr) | 1995-05-05 | 1997-05-30 | Adir | Utilisation des derives du benzopyrane pour l'obtention de compositions pharmaceutiques destinees au traitement des pathologies liees a l'echangeur c1-/hc03-, na+ independant |
| JPH0967336A (ja) | 1995-09-04 | 1997-03-11 | Kanebo Ltd | 新規なイソチオウレア誘導体 |
| KR20010005632A (ko) | 1997-03-27 | 2001-01-15 | 우에하라 아끼라 | 2-페녹시아닐린 유도체 |
| JPH1149752A (ja) * | 1997-08-05 | 1999-02-23 | Taisho Pharmaceut Co Ltd | フェノキシピリジン誘導体 |
| DE19742508A1 (de) * | 1997-09-26 | 1999-04-01 | Hoechst Marion Roussel De Gmbh | Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| US6162832A (en) | 1997-10-20 | 2000-12-19 | Taisho Pharmaceutical Co., Inc. | 2-Phenoxyaniline derivatives |
| JPH11302235A (ja) | 1998-04-15 | 1999-11-02 | Taisho Pharmaceut Co Ltd | フェノキシアルキルアミン誘導体 |
| CA2370607A1 (en) | 1999-04-23 | 2000-11-02 | Bristol-Myers Squibb Company | Bicyclic acyl guanidine sodium/proton exchange inhibitors and method |
| WO2001021610A1 (en) * | 1999-09-17 | 2001-03-29 | Nissan Chemical Industries, Ltd. | Benzopyran derivative |
| FI20011507A0 (fi) * | 2001-07-10 | 2001-07-10 | Orion Corp | Uusia yhdisteitä |
-
2003
- 2003-01-09 FI FI20030030A patent/FI20030030A0/fi unknown
-
2004
- 2004-01-08 AR ARP040100052A patent/AR042733A1/es unknown
- 2004-01-09 CA CA002512184A patent/CA2512184A1/en not_active Abandoned
- 2004-01-09 BR BR0406669-3A patent/BRPI0406669A/pt not_active IP Right Cessation
- 2004-01-09 WO PCT/FI2004/000011 patent/WO2004063191A1/en active Application Filing
- 2004-01-09 NZ NZ541087A patent/NZ541087A/en unknown
- 2004-01-09 PL PL378326A patent/PL378326A1/pl not_active Application Discontinuation
- 2004-01-09 US US10/541,677 patent/US7482340B2/en not_active Expired - Fee Related
- 2004-01-09 CN CNB200480003357XA patent/CN100457752C/zh not_active Expired - Fee Related
- 2004-01-09 RS YUP-2005/0528A patent/RS20050528A/sr unknown
- 2004-01-09 KR KR1020057012621A patent/KR20050095601A/ko not_active Application Discontinuation
- 2004-01-09 JP JP2006500151A patent/JP2006516271A/ja active Pending
- 2004-01-09 EA EA200501104A patent/EA008539B1/ru not_active IP Right Cessation
- 2004-01-09 EP EP04701023A patent/EP1583759A1/en not_active Withdrawn
- 2004-01-09 MX MXPA05007435A patent/MXPA05007435A/es active IP Right Grant
- 2004-01-09 AU AU2004203943A patent/AU2004203943B2/en not_active Ceased
- 2004-09-01 UA UAA200507847A patent/UA81941C2/uk unknown
-
2005
- 2005-06-28 IL IL169435A patent/IL169435A0/en unknown
- 2005-08-02 IS IS7969A patent/IS7969A/is unknown
- 2005-08-03 NO NO20053730A patent/NO20053730L/no not_active Application Discontinuation
- 2005-08-08 HR HR20050703A patent/HRP20050703A2/hr not_active Application Discontinuation
-
2006
- 2006-01-24 ZA ZA200505461A patent/ZA200505461B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA81941C2 (uk) | 2008-02-25 |
| CN100457752C (zh) | 2009-02-04 |
| US20060241147A1 (en) | 2006-10-26 |
| NZ541087A (en) | 2008-04-30 |
| US7482340B2 (en) | 2009-01-27 |
| MXPA05007435A (es) | 2005-09-12 |
| IS7969A (is) | 2005-08-02 |
| PL378326A1 (pl) | 2006-03-20 |
| RS20050528A (en) | 2007-06-04 |
| JP2006516271A (ja) | 2006-06-29 |
| AU2004203943B2 (en) | 2009-09-17 |
| CN1745078A (zh) | 2006-03-08 |
| BRPI0406669A (pt) | 2005-12-20 |
| EP1583759A1 (en) | 2005-10-12 |
| FI20030030A0 (fi) | 2003-01-09 |
| NO20053730D0 (no) | 2005-08-03 |
| EA200501104A1 (ru) | 2005-12-29 |
| KR20050095601A (ko) | 2005-09-29 |
| IL169435A0 (en) | 2007-07-04 |
| ZA200505461B (en) | 2006-03-29 |
| HRP20050703A2 (en) | 2005-10-31 |
| WO2004063191A1 (en) | 2004-07-29 |
| CA2512184A1 (en) | 2004-07-29 |
| NO20053730L (no) | 2005-10-07 |
| AU2004203943A1 (en) | 2004-07-29 |
| EA008539B1 (ru) | 2007-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042733A1 (es) | Derivados de piridinas utilizados como inhibidores del mecanismo de intercambio na+/ca2+ | |
| AR046779A1 (es) | Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer. | |
| AR045761A1 (es) | Derivados de 2-piridona como inhibidores de elastasa de neutrofilos | |
| AR046083A1 (es) | Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos | |
| CR7548A (es) | Derivados de triazole como antagonistas del receptor de tachykinin | |
| CO5640136A2 (es) | Derivados de hexahidropiridoisoquinolinas inhibidores de dpp-iv y composiciones farmaceuticas que los contienen | |
| AR033306A1 (es) | Compuestos | |
| AR067327A1 (es) | Derivados de piperidina / piperazina | |
| AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR035153A1 (es) | Derivados de carboxamidas y cetonas de dihidrobenzodioxina | |
| AR060875A1 (es) | Derivados de 2-piridona como inhibidores de la neutrofilo elastasa humana | |
| AR039124A1 (es) | Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR045698A1 (es) | Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 | |
| RU2007138937A (ru) | Производные 1-бензилиндол-2-карбоксамида | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| AR066153A1 (es) | Derivados de piperidina / piperazina | |
| AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
| AR069146A1 (es) | Derivados de pirimidina, composicion farmaceutica que los comprende y el uso de esta para el tratamiento de enfermedades relacionadas con la activacion del sistema inmunitario. | |
| AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
| AR052330A1 (es) | Derivados de adamantano que comprenden quinoleinas sustituidas | |
| AR050208A1 (es) | Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
| PE20040698A1 (es) | Derivados de isoindolina | |
| PE20081315A1 (es) | Derivados de benzimidazol como antagonistas de vr-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |